NEW YORK, March 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Pharmaceutical Market: United Kindom
Espicom market intelligence, brought to you by Business Monitor International
OVERVIEW OF THE PHARMACEUTICAL MARKET IN UNITED KINGDOM
Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing schemes for medicines allow for budget control, as well as providing patients with access to highly innovative treatments. Guidance drafted by the National Institute for Health and Clinical Excellence (NICE) has recommended the use of Bristol-Myers Squibb 's Yervoy (ipilimumab) and Roche's Zelboraf ( vemurafenib) for the treatment of advanced skin cancer. These are the first new drugs approved for routine use by the UK's National Health Service for the disease in more than a decade. While this is positive news for both drugmakers, NICE's stamp of approval came only after the manufacturers of both drugs agreed to offer discounts, overturning a prior rejection of the treatments by the watchdog.
Headline Expenditure Projections:
Pharmaceuticals : GBP23.81bn (US$38.33bn) in 2011 to GBP23.74bn (US$37.27bn) in 2012; -0.3% in local currency terms and -2.8% in US dollar terms. Forecast unchanged from Q4 12.
Healthcare : GBP144.79bn (US$232.99bn) in 2011 to GBP149.35bn (US$234.48bn) in 2012; +3.2% in local currency terms and +0.6% in US dollar terms. Forecast unchanged from Q4 12.
Medical devices : GBP5.89bn (US$9.48nn) in 2011 to GBP5.93bn (US$9.30bn) in 2012; +0.6% in local currency terms and -1.9% in US dollar terms. Forecast unchanged from Q4 12.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Table of Contents
SWOT Analysis 9
UK Pharmaceuticals And Healthcare Industry SWOT 9
UK Political SWOT 10
UK Economic SWOT 10
UK Business Environment SWOT 11
Pharmaceutical Business Environment Ratings 12
Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q113 12
Rewards 14
Risks 14
UK Market Summary 16
Regulatory Regime 17
Pharmaceutical Advertising 18
Intellectual Property Issues 19
Pricing Regime 20
Generic Drug Prices 23
Generic Substitution 24
OTC Prices 26
Reimbursement Regime 26
Patient Access Scheme 27
Table: Patient Access Schemes in Published Guidance, 2007-10 29
Patient Involvement in NHS 30
Industry Trends And Developments 31
Epidemiology 31
Non-Communicable Disease 31
Communicable Diseases 34
Healthcare Sector 34
Healthcare Reforms 35
Healthcare Funding 36
Healthcare IT 37
Health Insurance 38
Research & Development 40
Biotechnology 42
Clinical Trials 43
Medical Devices 45
Industry Forecast Scenario 46
Pharmaceutical Market Forecast 46
Table: Pharmaceutical Sales Indicators,2008-2016 47
Healthcare Market Forecast 48
Table: Healthcare Expenditure Indicators, 2008-2016 49
Table: Healthcare Governmental Indicators, 2008-2016 50
Table: Healthcare Private Indicators, 2008-2016 50
Key Growth Factors – Macroeconomic 51
Table: Macroeconomic Activity 54
Prescription Drug Market Forecast 55
Table: Prescriptions & Cost by Therapeutic Area in the UK, 2011 55
Table: Written Prescriptions, 2007-2011 (mn) 59
Table: Prescriptions by Value, 2007-11 (GBPmn) 59
Table: Prescription Drug Sales Indicators, 2008-2016 60
Patented Drug Market Forecast 61
Table: Patented Drug Market Indicators, 2008-2016 62
Generic Drug Market Forecast 63
Table: Prescriptions Written and Dispensed Generically in England by Value, 1996-11 (GBPmn) 63
Table: Generic Prescribing Rates by Therapeutic Area in England, 2006-11 (% by Volume) 64
Table: Generic Dispensing Rates by Therapeutic Area in England, 2006-11 (% by Volume) 64
Table: Generic Drug Sales Indicators, 2008-2016 66
OTC Medicine Market Forecast 67
Table: OTC Sales by Therapeutic Category at Retail Prices, 2008-11 (GBPmn) 68
Table: OTC Medicine Sales Indicators, 2008-2016 71
Table: Medicine Sales Breakdown, 2005-2010 71
Pharmaceutical Trade Forecast 72
Table: Exports and Imports Indicators, 2008-2016 74
Medical Device Market Forecast 75
Table: Medical Devices Sales Indicators 2008-2016 75
Other Healthcare Data 77
Key Risks To BMI Forecasts 78
Competitive Landscape 79
Pharmaceutical Industry 79
Table: Pharmaceutical Production, 1995-10 (Euros 000s) 79
Table: Top 20 UK-Based Pharmaceutical Companies According To Market Capitalisation 80
Table: Top 20 UK-Based Biotechnology Companies According To Market Capitalisation 81
Pharmaceutical Trade Associations 82
Table: Association of British Pharmaceutical Industry (ABPI) Full Members, 2011 82
Table: Members of the British Generic Manufacturers Association, 2012 84
Table: Full Members of the Proprietary Association of Great Britain (PAGB), 2011 84
Company Developments 85
Wholesale Sector 86
Table: Members of British Association of Pharmaceutical Wholesalers (BAPW), 2011 86
Retail Sector 88
Table: UK Registered Retail Pharmacies, 2010 91
Company Profiles 92
Leading Local Manufacturers 92
GlaxoSmithKline 92
AstraZeneca 97
Leading Multinational Manufacturers 103
Pfizer 103
Novartis 105
Sanofi 107
Merck & Co 109
Demographic Outlook 110
Table: The United Kingdom's Population By Age Group, 1990-2020 ('000) 111
Table: The United Kingdom's Population By Age Group, 1990-2020 (% of total) 111
Table: The United Kingdom's Key Population Ratios, 1990-2020 112
Table: The United Kingdom's Rural And Urban Population, 1990-2020 113
Glossary 114
BMI Methodology 116
How We Generate Our Pharmaceutical Industry Forecasts 116
Risk/Reward Ratings Methodology 117
Ratings Overview 117
Table: Pharmaceutical Business Environment Indicators 118
Weighting 119
Table: Weighting Of Components 119
To order this report:
Drug_and_Medication Industry: The Pharmaceutical Market: United Kindom
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article